A comparison of the combination of atropine and glycopyrrolate with atropine alone for the reversal of muscle relaxant
- PMID: 25265768
A comparison of the combination of atropine and glycopyrrolate with atropine alone for the reversal of muscle relaxant
Abstract
Background: Muscle relaxant is commonly used in general anesthesia to facilitate surgery. When finishing the operation, anesthesiologists reverse the muscle relaxant with anticholinesterase, neostigmine, combined with anticholinergic for prevention of unwanted side effects from neostigmine. The only existed anticholinergic in Thailand is atropine, which has a more rapid onset than neostigmine resulting in initial tachycardia. Lately, we have glycopyrrolate that cause less increase in initial heart rate. Therefore, we would like to study the effect of heart rate of the combination between atropine and glycopyrrolate to counteract the effect of neostigmine.
Objective: Evaluate the different increase in heart rate after the reversal of muscle relaxant with neostigmine combined with atropine or glycopyrrolate plus atropine.
Material and method: The study was a randomized controlled trial study. Fifty-one, ASA I or II patients undergoing elective gynecological surgery under general anesthesia technique were enrolled in the present study. They were randomly assigned by computer-generated random sequence into two groups, control group and intervention group. Control group received neostigmine 2.5 mg and atropine 1.2 mg, intervention group received neostigmine 2.5 mg, glycopyrrolate 0.2 mg and atropine 0.6 mg for reversal of neuromuscular block after finishing the operation. Both groups received the same anesthetic agents including muscle relaxant. Heart rate was recorded before drugs administration and at 1, 3, 5, and 7 minutes after injection. We also recorded heart rate in the PA CU at 0, 15, 30, 45, and 60 minutes. Secondary outcome was incidence of arrhythmia during the observation in PACU.
Results: There was no difference in age and baseline heart rate between the two groups. There was no different increase in heart rate after administration of reversal agent between control group and intervention group at any time (p-value = 0.496). No incidence of significant arrhythmia in both groups.
Conclusion: There is no significant different increase in heart rate in 0.2 mg glycopyrrolate plus 0.6 mg atropine group compared to 1.2 mg atropine alone for antagonizing muscarinic effects of 2.5 mg neostigmine. Therefore, atropine 0.6 mg and glycopyrrolate 0.2 mg is an alternative to antagonize muscarinic effects of neostigmine.
Similar articles
-
Less tachycardia in adults when using atropine 0.9 mg compared with 1.2 mg plus neostigmine 2.5 mg.J Med Assoc Thai. 2008 May;91(5):665-8. J Med Assoc Thai. 2008. PMID: 18672629 Clinical Trial.
-
Sugammadex reversal of rocuronium-induced neuromuscular blockade: a comparison with neostigmine-glycopyrrolate and edrophonium-atropine.Anesth Analg. 2007 Mar;104(3):569-74. doi: 10.1213/01.ane.0000248224.42707.48. Anesth Analg. 2007. PMID: 17312210 Clinical Trial.
-
Effects of Anticholinesterase Reversal Under General Anesthesia on Postoperative Cardiovascular Complications: A Retrospective Cohort Study.Anesth Analg. 2020 Mar;130(3):685-695. doi: 10.1213/ANE.0000000000004099. Anesth Analg. 2020. PMID: 30896593
-
Atrio-ventricular Block Following Neostigmine-Glycopyrrolate Reversal in Non-heart Transplant Patients: Case Report.Anesth Prog. 2018 Fall;65(3):187-191. doi: 10.2344/anpr-65-03-10. Anesth Prog. 2018. PMID: 30235426 Free PMC article. Review.
-
Glycopyrrolate: It's time to review.J Clin Anesth. 2017 Feb;36:51-53. doi: 10.1016/j.jclinane.2016.09.013. Epub 2016 Nov 18. J Clin Anesth. 2017. PMID: 28183573 Review.